14.56
-0.86 (-5.58%)
| 前收盘价格 | 15.42 |
| 收盘价格 | 15.37 |
| 成交量 | 100,495 |
| 平均成交量 (3个月) | 458,268 |
| 市值 | 450,294,912 |
| 预期市盈率 (P/E Forward) | 10.29 |
| 价格/销量 (P/S) | 4.33 |
| 52周波幅 | |
| 利润日期 | 5 Nov 2026 |
| 营业毛利率 | -79.61% |
| 营业利益率 (TTM) | -63.88% |
| 稀释每股收益 (EPS TTM) | -2.19 |
| 季度收入增长率 (YOY) | 66.70% |
| 总债务/股东权益 (D/E MRQ) | 1,022.12% |
| 流动比率 (MRQ) | 2.09 |
| 营业现金流 (OCF TTM) | -38.38 M |
| 杠杆自由现金流 (LFCF TTM) | -149.68 M |
| 资产报酬率 (ROA TTM) | -38.35% |
| 股东权益报酬率 (ROE TTM) | -407.50% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Medical Devices (US) | 混合的 | 混合的 |
| Medical Devices (全球的) | 混合的 | 混合的 | |
| 股票 | Avita Medical, Inc. | 混合的 | 看跌 |
AIStockmoo 评分
| 分析师共识 | NA |
| 内部交易活动 | NA |
| 价格波动 | -5.0 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | 4.0 |
| 相对估值 | NA |
| 财务健康 | NA |
| AI Insight | NA |
| 平均 | 0.50 |
|
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently in rollout across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US. |
|
| 部门 | Healthcare |
| 行业 | Medical Devices |
| 投资方式 | Small Value |
| 内部持股比例 | 0.83% |
| 机构持股比例 | 26.79% |
该时间范围内无数据。
该时间范围内无数据。
AI 技术分析
打开“技术”标签以生成最新分析。
投资组合